Symbols / BIVI $1.42 +2.90% BioVie Inc.
BIVI Chart
About
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 10.71M |
| Enterprise Value | -9.52M | Income | -17.48M | Sales | — |
| Book/sh | 2.56 | Cash/sh | 2.72 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -0.32 | PEG | — |
| P/S | — | P/B | 0.56 | P/C | — |
| EV/EBITDA | 0.53 | EV/Sales | — | Quick Ratio | 6.90 |
| Current Ratio | 7.25 | Debt/Eq | 1.64 | LT Debt/Eq | — |
| EPS (ttm) | -3.28 | EPS next Y | -4.41 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-11 | ROA | -47.20% |
| ROE | -80.74% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 7.54M |
| Shs Float | 7.50M | Short Float | 2.04% | Short Ratio | 1.68 |
| Short Interest | — | 52W High | 13.20 | 52W Low | 1.06 |
| Beta | 0.56 | Avg Volume | 89.83K | Volume | 47.88K |
| Target Price | — | Recom | None | Prev Close | $1.38 |
| Price | $1.42 | Change | 2.90% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.43
Latest analyst target
3. DCF / Fair value
$-19.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.43
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-07-01 | init | ThinkEquity | — → Buy | $3 |
| 2023-11-30 | main | Oppenheimer | Outperform → Outperform | $5 |
| 2023-08-22 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2023-07-18 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2023-05-17 | reit | Cantor Fitzgerald | Overweight → Overweight | $11 |
| 2023-05-17 | reit | Oppenheimer | Outperform → Outperform | $12 |
| 2023-02-14 | reit | Oppenheimer | — → Outperform | $12 |
| 2022-09-28 | main | EF Hutton | — → Buy | $8 |
| 2022-07-22 | init | Cantor Fitzgerald | — → Overweight | $7 |
| 2022-03-17 | main | EF Hutton | — → Buy | $14 |
| 2022-03-15 | init | Oppenheimer | — → Outperform | $9 |
| 2021-11-30 | main | B. Riley Securities | — → Buy | $27 |
| 2021-01-15 | init | B. Riley FBR | — → Buy | $47 |
- If You Invested $1,000 in Biovie Inc (BIVI) - Stock Titan Mon, 06 Apr 2026 01
- BIVI Tests Key Support at $1.20 in Range-Bound Downtrend - Bitget Mon, 06 Apr 2026 09
- What Makes BioVie (BIVI) a New Buy Stock - finance.yahoo.com hu, 11 Dec 2025 08
- Parkinson’s trial drug heads to 2026 Alzheimer’s & Parkinson’s meeting - Stock Titan hu, 12 Mar 2026 07
- BIVI Should I Buy - Intellectia AI Wed, 01 Apr 2026 09
- Should I buy BioVie (BIVI) - Zacks Investment Research hu, 11 Dec 2025 08
- symbol__ Stock Quote Price and Forecast - CNN hu, 16 Nov 2023 01
- BioVie To Carry Out 1-for-10 Reverse Stock Split On July 7th, 2025 - moomoo.com ue, 01 Jul 2025 07
- BioVie (NASDAQ: BIVI) CEO Cuong Do discloses 5.03% share stake - Stock Titan Wed, 25 Mar 2026 07
- BIVI Forecast — Price Prediction for 2026. Should I Buy BIVI? - Intellectia AI ue, 27 May 2025 09
- BIVI Stock Price and Chart — NASDAQ:BIVI - TradingView Mon, 21 Sep 2020 19
- BIVI Surges 10% Without Clear Catalyst — Traders on Edge - Bitget Fri, 20 Mar 2026 07
- BioVie Inc. Announces Closing of $12 Million Public Offering - finance.yahoo.com Mon, 11 Aug 2025 07
- Biovie Stock Price Forecast. Should You Buy BIVI? - StockInvest.us hu, 10 Dec 2020 13
- Alzheimer's and Long COVID research heads to 2026 psychiatry meeting - Stock Titan hu, 12 Feb 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
18.07
-43.86%
|
32.18
-28.62%
|
45.08
+65.41%
|
27.25
|
| Research And Development |
|
9.27
-59.88%
|
23.10
-30.63%
|
33.30
+92.95%
|
17.26
|
| Selling General And Administration |
|
8.57
-3.16%
|
8.85
-23.39%
|
11.55
+18.29%
|
9.77
|
| Total Expenses |
|
18.07
-43.86%
|
32.18
-28.62%
|
45.08
+65.41%
|
27.25
|
| Operating Income |
|
-18.07
+43.86%
|
-32.18
+28.62%
|
-45.08
-65.41%
|
-27.25
|
| Total Operating Income As Reported |
|
-18.07
+43.86%
|
-32.18
+28.62%
|
-45.08
-65.41%
|
-27.25
|
| EBITDA |
|
-16.98
+41.44%
|
-29.00
+36.59%
|
-45.73
-93.00%
|
-23.69
|
| Normalized EBITDA |
|
-16.98
+44.88%
|
-30.81
+30.43%
|
-44.29
-64.16%
|
-26.98
|
| Reconciled Depreciation |
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
|
| EBIT |
|
-17.21
+41.12%
|
-29.23
+36.40%
|
-45.96
-92.11%
|
-23.92
|
| Total Unusual Items |
|
0.00
-99.79%
|
1.82
+226.35%
|
-1.44
-143.73%
|
3.29
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-99.79%
|
1.82
+226.35%
|
-1.44
-143.73%
|
3.29
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-17.54
+45.39%
|
-32.12
+36.09%
|
-50.26
-92.67%
|
-26.08
|
| Pretax Income |
|
-17.54
+45.39%
|
-32.12
+36.09%
|
-50.26
-92.67%
|
-26.08
|
| Net Non Operating Interest Income Expense |
|
0.52
+129.61%
|
-1.76
+52.99%
|
-3.74
-76.41%
|
-2.12
|
| Interest Expense Non Operating |
|
0.33
-88.50%
|
2.89
-32.70%
|
4.30
+98.81%
|
2.16
|
| Net Interest Income |
|
0.52
+129.61%
|
-1.76
+52.99%
|
-3.74
-76.41%
|
-2.12
|
| Interest Expense |
|
0.33
-88.50%
|
2.89
-32.70%
|
4.30
+98.81%
|
2.16
|
| Interest Income Non Operating |
|
0.85
-24.96%
|
1.14
+102.17%
|
0.56
+1175.55%
|
0.04
|
| Interest Income |
|
0.85
-24.96%
|
1.14
+102.17%
|
0.56
+1175.55%
|
0.04
|
| Other Income Expense |
|
0.00
-99.79%
|
1.82
+226.35%
|
-1.44
-143.73%
|
3.29
|
| Gain On Sale Of Security |
|
0.00
-99.79%
|
1.82
+226.35%
|
-1.44
-143.73%
|
3.29
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-17.54
+45.39%
|
-32.12
+36.09%
|
-50.26
-92.67%
|
-26.08
|
| Net Income From Continuing Operation Net Minority Interest |
|
-17.54
+45.39%
|
-32.12
+36.09%
|
-50.26
-92.67%
|
-26.08
|
| Net Income From Continuing And Discontinued Operation |
|
-17.54
+45.39%
|
-32.12
+36.09%
|
-50.26
-92.67%
|
-26.08
|
| Net Income Continuous Operations |
|
-17.54
+45.39%
|
-32.12
+36.09%
|
-50.26
-92.67%
|
-26.08
|
| Normalized Income |
|
-17.55
+48.30%
|
-33.94
+30.48%
|
-48.82
-66.21%
|
-29.37
|
| Net Income Common Stockholders |
|
-17.91
+45.73%
|
-33.01
+34.32%
|
-50.26
-92.67%
|
-26.08
|
| Otherunder Preferred Stock Dividend |
|
0.37
-58.32%
|
0.89
|
0.00
|
0.00
|
| Diluted EPS |
|
-12.12
+83.41%
|
-73.05
+52.78%
|
-154.70
-45.94%
|
-106.00
|
| Basic EPS |
|
-12.12
+83.41%
|
-73.05
+52.78%
|
-154.70
-45.94%
|
-106.00
|
| Basic Average Shares |
|
1.48
+226.96%
|
0.45
+39.10%
|
0.32
+31.71%
|
0.25
|
| Diluted Average Shares |
|
1.48
+226.96%
|
0.45
+39.10%
|
0.32
+31.71%
|
0.25
|
| Diluted NI Availto Com Stockholders |
|
-17.91
+45.73%
|
-33.01
+34.32%
|
-50.26
-92.67%
|
-26.08
|
| Amortization |
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
|
| Amortization Of Intangibles Income Statement |
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
|
| Depreciation Amortization Depletion Income Statement |
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
|
| Depreciation And Amortization In Income Statement |
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Total Assets |
|
21.56
-14.46%
|
25.21
-28.19%
|
35.10
|
| Current Assets |
|
20.70
-13.93%
|
24.05
-29.36%
|
34.04
|
| Cash Cash Equivalents And Short Term Investments |
|
17.54
-26.42%
|
23.84
-29.74%
|
33.94
|
| Cash And Cash Equivalents |
|
17.54
-26.42%
|
23.84
+22.52%
|
19.46
|
| Cash Equivalents |
|
13.57
+22.44%
|
11.08
-15.78%
|
13.16
|
| Cash Financial |
|
3.98
-68.83%
|
12.76
+102.46%
|
6.30
|
| Other Short Term Investments |
|
—
|
0.00
-100.00%
|
14.48
|
| Receivables |
|
2.10
|
0.00
|
—
|
| Other Receivables |
|
2.10
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
| Other Current Assets |
|
1.05
+413.67%
|
0.20
+99.36%
|
0.10
|
| Total Non Current Assets |
|
0.86
-25.55%
|
1.16
+9.08%
|
1.06
|
| Net PPE |
|
0.34
-16.49%
|
0.41
+403.44%
|
0.08
|
| Gross PPE |
|
0.34
-16.49%
|
0.41
+403.44%
|
0.08
|
| Properties |
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.34
-16.49%
|
0.41
+403.44%
|
0.08
|
| Other Properties |
|
—
|
—
|
0.08
|
| Goodwill And Other Intangible Assets |
|
0.52
-30.44%
|
0.75
-23.34%
|
0.98
|
| Goodwill |
|
0.35
+0.00%
|
0.35
+0.00%
|
0.35
|
| Other Intangible Assets |
|
0.18
-56.26%
|
0.41
-36.00%
|
0.64
|
| Other Non Current Assets |
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
2.55
-73.71%
|
9.70
-50.91%
|
19.76
|
| Current Liabilities |
|
2.27
-75.68%
|
9.35
-35.48%
|
14.49
|
| Payables And Accrued Expenses |
|
2.20
-38.66%
|
3.59
+3.18%
|
3.48
|
| Current Debt And Capital Lease Obligation |
|
0.07
-98.71%
|
5.76
-37.03%
|
9.15
|
| Current Debt |
|
—
|
5.70
-37.38%
|
9.11
|
| Other Current Borrowings |
|
—
|
5.70
-37.38%
|
9.11
|
| Current Capital Lease Obligation |
|
0.07
+23.40%
|
0.06
+34.37%
|
0.04
|
| Other Current Liabilities |
|
—
|
0.00
-99.80%
|
1.87
|
| Total Non Current Liabilities Net Minority Interest |
|
0.28
-21.28%
|
0.35
-93.36%
|
5.27
|
| Long Term Debt And Capital Lease Obligation |
|
0.28
-21.28%
|
0.35
-93.36%
|
5.27
|
| Long Term Debt |
|
—
|
—
|
5.23
|
| Long Term Capital Lease Obligation |
|
0.28
-21.28%
|
0.35
+723.18%
|
0.04
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
| Stockholders Equity |
|
19.01
+22.61%
|
15.51
+1.08%
|
15.34
|
| Common Stock Equity |
|
19.01
+22.61%
|
15.51
+1.08%
|
15.34
|
| Capital Stock |
|
0.01
+20.02%
|
0.01
+70.99%
|
0.00
|
| Common Stock |
|
0.01
+20.02%
|
0.01
+70.99%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
1.92
+208.39%
|
0.62
+70.54%
|
0.36
|
| Ordinary Shares Number |
|
1.91
+209.24%
|
0.62
+69.92%
|
0.36
|
| Treasury Shares Number |
|
0.00
+7.79%
|
0.00
+1054.39%
|
0.00
|
| Additional Paid In Capital |
|
371.15
+6.12%
|
349.73
+10.54%
|
316.39
|
| Retained Earnings |
|
-352.14
-5.36%
|
-334.23
-10.96%
|
-301.23
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
0.00
-100.00%
|
0.18
|
| Treasury Stock |
|
0.00
+7.41%
|
0.00
+1250.00%
|
0.00
|
| Other Equity Adjustments |
|
—
|
—
|
0.18
|
| Total Equity Gross Minority Interest |
|
19.01
+22.61%
|
15.51
+1.08%
|
15.34
|
| Total Capitalization |
|
19.01
+22.61%
|
15.51
-24.61%
|
20.57
|
| Working Capital |
|
18.42
+25.37%
|
14.70
-24.82%
|
19.55
|
| Invested Capital |
|
19.01
-10.35%
|
21.21
-28.53%
|
29.67
|
| Total Debt |
|
0.35
-94.27%
|
6.11
-57.62%
|
14.42
|
| Capital Lease Obligations |
|
0.35
-14.71%
|
0.41
+369.30%
|
0.09
|
| Net Tangible Assets |
|
18.49
+25.32%
|
14.75
+2.75%
|
14.36
|
| Tangible Book Value |
|
18.49
+25.32%
|
14.75
+2.75%
|
14.36
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-19.03
+31.92%
|
-27.95
+30.58%
|
-40.25
-111.96%
|
-18.99
|
| Cash Flow From Continuing Operating Activities |
|
-19.03
+31.92%
|
-27.95
+30.58%
|
-40.25
-111.96%
|
-18.99
|
| Net Income From Continuing Operations |
|
-17.54
+45.39%
|
-32.12
+36.09%
|
-50.26
-92.67%
|
-26.08
|
| Depreciation Amortization Depletion |
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
|
| Amortization Cash Flow |
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
|
| Depreciation And Amortization |
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
|
| Amortization Of Intangibles |
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
+0.00%
|
0.23
|
| Other Non Cash Items |
|
0.22
-84.72%
|
1.41
-36.67%
|
2.23
+84.88%
|
1.21
|
| Stock Based Compensation |
|
2.47
-46.96%
|
4.66
-26.90%
|
6.38
+2.93%
|
6.19
|
| Operating Gains Losses |
|
-0.00
+99.82%
|
-2.04
-241.92%
|
1.44
+143.73%
|
-3.29
|
| Gain Loss On Investment Securities |
|
-0.00
+99.82%
|
-2.04
-241.92%
|
1.44
+143.73%
|
-3.29
|
| Change In Working Capital |
|
-4.40
-4962.57%
|
-0.09
+67.89%
|
-0.27
-109.83%
|
2.75
|
| Change In Receivables |
|
-2.10
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
-0.85
-730.02%
|
-0.10
-355.21%
|
0.04
+181.54%
|
-0.05
|
| Change In Payables And Accrued Expense |
|
-1.39
-1353.10%
|
0.11
-89.29%
|
1.03
-28.55%
|
1.45
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
-0.05
|
| Change In Other Current Liabilities |
|
-0.06
+36.90%
|
-0.10
+92.88%
|
-1.34
-199.30%
|
1.35
|
| Investing Cash Flow |
|
0.00
-100.00%
|
14.53
+201.57%
|
-14.30
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
0.00
-100.00%
|
14.53
+201.57%
|
-14.30
|
0.00
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
14.53
+201.57%
|
-14.30
|
0.00
|
| Purchase Of Investment |
|
—
|
—
|
-14.30
|
0.00
|
| Sale Of Investment |
|
0.00
-100.00%
|
14.53
|
—
|
—
|
| Financing Cash Flow |
|
12.73
-28.52%
|
17.80
-67.85%
|
55.37
+67.18%
|
33.12
|
| Cash Flow From Continuing Financing Activities |
|
12.73
-28.52%
|
17.80
-67.85%
|
55.37
+67.18%
|
33.12
|
| Net Issuance Payments Of Debt |
|
-5.85
|
0.00
|
0.00
-100.00%
|
14.61
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
14.61
|
| Repayment Of Debt |
|
-5.85
|
0.00
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
14.61
|
| Long Term Debt Payments |
|
—
|
-10.00
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
-10.00
|
0.00
-100.00%
|
14.61
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
14.61
|
| Short Term Debt Payments |
|
-5.85
|
0.00
|
—
|
—
|
| Net Short Term Debt Issuance |
|
-5.85
|
0.00
|
—
|
14.61
|
| Net Common Stock Issuance |
|
15.67
-43.62%
|
27.80
-49.79%
|
55.37
+199.12%
|
18.51
|
| Proceeds From Stock Option Exercised |
|
2.90
+129.01%
|
-10.00
-446528.57%
|
0.00
|
0.00
|
| Changes In Cash |
|
-6.30
-243.72%
|
4.38
+435.05%
|
0.82
-94.20%
|
14.13
|
| Beginning Cash Position |
|
23.84
+22.52%
|
19.46
+4.39%
|
18.64
+313.19%
|
4.51
|
| End Cash Position |
|
17.54
-26.42%
|
23.84
+22.52%
|
19.46
+4.39%
|
18.64
|
| Free Cash Flow |
|
-19.03
+31.92%
|
-27.95
+30.58%
|
-40.25
-111.96%
|
-18.99
|
| Interest Paid Supplemental Data |
|
0.18
-87.94%
|
1.53
-27.60%
|
2.11
+118.46%
|
0.96
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
0.00
|
| Common Stock Issuance |
|
15.67
-43.62%
|
27.80
-49.79%
|
55.37
+199.12%
|
18.51
|
| Issuance Of Capital Stock |
|
15.67
-43.62%
|
27.80
-49.79%
|
55.37
+199.12%
|
18.51
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-02-06 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 8-K2025-11-13 View
- 8-K2025-11-12 View
- 10-Q2025-11-10 View
- 10-K2025-08-15 View
- 42025-08-13 View
- 8-K2025-08-11 View
- 8-K2025-07-23 View
- 8-K2025-06-27 View
- 8-K2025-06-24 View
- 10-Q2025-05-12 View
- 8-K2025-03-28 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|